Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities
| Autor: | Pak Yui Fong, Shing Chuen Chow, Bernard Ming Hong Kwong, Charlene Cheuk Lam Lau, Christy Yik Ching Lau, Athena Hoi Ting Lee, Ha Ying Nip, Cheuk Yin Wong, Benedict Tsz Hin Yan, Ho Yin Chung |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Journal of Clinical Rheumatology and Immunology, Vol 20, Iss 1, Pp 25-34 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2661-3417 2661-3425 26613417 |
| DOI: | 10.1142/S2661341720300013 |
| Popis: | Immune checkpoint inhibitors (ICIs) have forged a new direction for the treatment of cancer. However, ICIs – programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors – are also known to cause immune-related adverse events (irAEs). Rheumatological adverse events are uncommon and often low grade, but flares of underlying rheumatological diseases may be triggered. Guidelines are available for the effective management of the rheumatological adverse events that more frequently arise from the use of ICIs, such as inflammatory arthritis, inflammatory myopathies, Sjogren syndrome, scleroderma, and polymyalgia rheumatica and eosinophilic fasciitis. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|